Therapy Areas: Oncology
Spherix awarded additional patent coverage in the US for pancreatic cancer
28 November 2019 -

Technology development company Spherix Inc (Nasdaq:SPEX) reported on Wednesday the receipt of additional patent coverage from the US Patent & Trademark Office in the field of pancreatic cancer.

Pancreatic cancer is reportedly the fourth most common cause of cancer-related deaths in the US and the eighth worldwide. The Pancreatic Cancer Action Network predicted that it will move from fourth to the second leading cause of cancer deaths in the US by 2020.

The US Patent, which has been assigned the number 10,463,684, was recently issued to the University of Texas at Austin and is being assigned to Spherix as part of the CBM BioPharma Inc asset acquisition.

According to the company, the patent targets, among other things, pancreatic cancer with a different mechanism than the current standard of care. The compound has been shown to be effective in cancer cells that are resistant to the current standard of care in preclinical studies.

Login
Username:

Password: